Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 211

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 6
Chunk 211
---
 that are inconsistent with such policy provided that they have considered those provisions
that must be included in the compensation policy according to the Companies Law and that shareholder approval was obtained (by a special
majority vote as discussed above with respect to the approval of director compensation that is inconsistent with the compensation policy).

In the case of a new chief
executive officer, the compensation committee may waive the shareholder approval requirement with regard to the compensation of a candidate
for the chief executive officer position if the compensation committee determines that: (i) the compensation arrangement is consistent
with the company’s compensation policy, (ii) the chief executive officer candidate did not have, on the date of his appointment
or during the two-year period preceding his appointment, an “affiliation” (including an employment relationship, a business
or professional relationship or control) with the company or a controlling shareholder of the company or a relative thereof and (iii)
subjecting the approval of the engagement to a shareholder vote would impede the company’s ability to employ the chief executive
officer candidate. However, if the chief executive officer candidate will serve as a member of the board of directors, such candidate’s
compensation terms as chief executive officer must be approved in accordance with the rules applicable to approval of compensation of
directors.

Compensation of Executive Officers and Directors

The aggregate cash compensation
and benefits in kind, paid by us and our subsidiaries to our executive officers and directors as a group for the year ended December 31,
2024 was approximately $4.0 million. This amount includes $231 of amounts set aside or accrued to provide pension, severance, retirement,
health or similar benefits or expenses as well as other benefits commonly reimbursed or paid by companies in Israel or the U. S. In addition,
in 2024 we granted to our executive officers and directors a total of 656,127 restricted share units and 3,390,570 options to purchase
our ordinary shares with a weighted average exercise price of $3.84. Both the share options and restricted share units commenced vesting
only following the consummation of the Business Combination. General vesting terms for the options and restricted share units will vest
over a 4-year period therefrom and the options typically expire 10 years from the date of grant. In certain cases our Board of Directors,
in line with the compensation policy approved by our shareholders, approved differing vesting terms for certain members of our senior
management or board of directors.

For 2025, we